Wells Fargo raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $250 from $235 and keeps an Overweight rating on the shares. The firm notes the company’s guidance came in ahead of investor expectations as Oxybate headwinds seem to be less than previously feared. Wells sees guidance as a clearing event for investors to get involved ahead of Zani’s potential GEA launch in the second half of the year.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals: Underappreciated Growth Story with Durable Sleep Franchise and Pipeline-Driven Upside
- Jazz Pharmaceuticals reports Q4 adjusted EPS $6.64 vs. $6.51 last year
- Jazz Pharmaceuticals sees FY26 revenue $4.25B-$4.5B, consensus $4.5B
- JAZZ Earnings this Week: How Will it Perform?
- ALX Oncology announces new data from Phase 1b/2 trial of evorpacept, Ziihera